CD274 and cancer: Antibodies targeting PD-L1 have shown clinical success in diverse cancers, including melanoma, leukemia, lymphoma, liver cancer, colorectal cancer, urothelial cancer, squamous-cell carcinoma of the head and neck, cervical cancer, kidney cancer, stomach cancer, and breast cancer [136,137].